Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3026887 | Thrombosis Research | 2016 | 6 Pages |
Abstract
In the presence of progestins, PS mRNA and protein expressions were significantly upregulated in HepG2 cells due to the augmentation of de novo PS mRNA expression modulated by RNA polymerase II (Pol II), thereby facilitating PS transcription elongation. Moreover, the transcription elongation inhibitor blocked progestin-mediated de novo PS mRNA expression. Conversely, progestin did not affect PROS1 promoter activity and PS mRNA stability. Pol II elongation efficiency in the newer-generation progestin (DRSP) treatment was not as strong compared with older-generation progestin (LNG), suggesting the difference in VTE risk between COC generations.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Toshihiro Kozuka, Shogo Tamura, Nami Kawamura, Yukiko Nakata, Ryo Hasebe, Ayumi Makiyama, Yuki Takagi, Moe Murata, Naoki Mizutani, Akira Takagi, Tetsuhito Kojima,